Café

© 2026 Longbridge｜Terms of Service Privacy Policy

NKGN

NKGN

0.00210.00%( 0.0000 )

LongbridgeAI

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ | NKGN Stock News

StockTitan

Mar 23, 2026 at 04:05 AM

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ | NKGN Stock News

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ | NKGN Stock News

Login to unlock191characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

NKGen Biotech

USNKGN

First Trust NYSE Arca Biotech Index Fd

USFBT

Health Care Select Sector SPDR

USXLV